Unknown

Dataset Information

0

Vemurafenib inhibits necroptosis in normal and pathological conditions as a RIPK1 antagonist.


ABSTRACT: Necroptosis, a programmed cell death with necrotic-like morphology, has been recognized as an important driver in various inflammatory diseases. Inhibition of necroptosis has shown potential promise in the therapy of multiple human diseases. However, very few necroptosis inhibitors are available for clinical use as yet. Here, we identified an FDA-approved anti-cancer drug, Vemurafenib, as a potent inhibitor of necroptosis. Through direct binding, Vemurafenib blocked the kinase activity of receptor-interacting protein kinases 1 (RIPK1), impeded the downstream signaling and necrosome complex assembly, and inhibited necroptosis. Compared with Necrostain-1, Vemurafenib stabilized RIPK1 in an inactive DLG-out conformation by occupying a distinct allosteric hydrophobic pocket. Furthermore, pretreatment with Vemurafenib provided strong protection against necroptosis-associated diseases in vivo. Altogether, our results demonstrate that Vemurafenib is an effective RIPK1 antagonist and provide rationale and preclinical evidence for the potential application of approved drug in necroptosis-related diseases.

SUBMITTER: Sun M 

PROVIDER: S-EPMC10449909 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Vemurafenib inhibits necroptosis in normal and pathological conditions as a RIPK1 antagonist.

Sun Mayu M   Ma Xueqi X   Mu Wei W   Li Haonan H   Zhao Xiaoming X   Zhu Tengfei T   Li Jingquan J   Yang Yongliang Y   Zhang Haibing H   Ba Qian Q   Wang Hui H  

Cell death & disease 20230824 8


Necroptosis, a programmed cell death with necrotic-like morphology, has been recognized as an important driver in various inflammatory diseases. Inhibition of necroptosis has shown potential promise in the therapy of multiple human diseases. However, very few necroptosis inhibitors are available for clinical use as yet. Here, we identified an FDA-approved anti-cancer drug, Vemurafenib, as a potent inhibitor of necroptosis. Through direct binding, Vemurafenib blocked the kinase activity of recept  ...[more]

Similar Datasets

| S-EPMC8501112 | biostudies-literature
2021-08-23 | GSE180024 | GEO
| S-EPMC9193967 | biostudies-literature
| S-EPMC9816173 | biostudies-literature
| S-EPMC5834731 | biostudies-literature
| S-EPMC9691486 | biostudies-literature
| S-EPMC4766406 | biostudies-literature
| S-EPMC6342007 | biostudies-literature
| S-EPMC5755685 | biostudies-literature
| S-EPMC8113527 | biostudies-literature